Price
$17.48-44.94%Social Signal Score
Analyst Ratings
20 analysts52-week range
- Last close
- $17.48
- Off 52w high
- -56.3%
- 200-day average
- $26.55
- vs 200-day
- -34.2%
Revenue
$890.37M+4832.13%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew Dudum
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 2,442
- Beta
- 2.50
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.06
Financials
Revenue
$890.37M+4832.1%Net Income
$-33.04MEBITDA
$-8.04MFree Cash Flow
$32.11MEPS (diluted)
$-0.14Shares Outstanding (diluted)
233.82M+510.8%Operating Expenses
$468.15MCash & Debt
$712.22MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.35B | $128.37M | $0.57 |
| 2024 | $1.48B | $126.04M | $0.58 |
| 2023 | $872.00M | $-23.55M | $-0.11 |
| 2022 | $526.92M | $-65.68M | $-0.32 |
| 2021 | $271.88M | $-107.66M | $-0.58 |
| 2020 | $148.76M | $-18.11M | $-0.51 |
| 2019 | $82.56M | $-72.06M | $-2.07 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.84
- Implied price
- $47.79
- Return from $14.60
- 26.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.76 — today's price is already 38.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 48 | 57 | 66 | 75 |
|---|---|---|---|---|---|
| -2.0% | 6.6% | 11.1% | 15.0% | 18.4% | 21.5% |
| 3.0% | 12.1% | 16.8% | 20.9% | 24.5% | 27.7% |
| 8.0% | 17.5% | 22.5% | 26.8% | 30.5% | 33.9% |
| 13.0% | 22.9% | 28.2% | 32.6% | 36.6% | 40.1% |
| 18.0% | 28.4% | 33.8% | 38.5% | 42.6% | 46.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
65+745.00%Social Signal Score
Mentions (100)
- Newscnbc.com·4d ago·Positive
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy Hims & Hers Health said it will now offer five new peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform. The telehealth company will now offer compounded formulations of sermorelin, glutathione, and NAD+, as well as vitamin B-12 and L-carnitine, none of which are approved by the FDA.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Hims & Hers: Further Expanding Internationally Hims & Hers Health is a Strong Buy: my $23.8 implied share price offers roughly 20% upside while targeting a 15% annual return. International expansion is the principal growth driver, with revenue guidance raised to at least $650 million in 2026 and $1 billion expected in 2027. HIMS faces near-term margin pressure and subscriber headwinds; Q3 gross margin fell to 57%, while subscribers declined by 103,000 sequentially.
View source ↗ - Newsfool.com·6d ago·Negative
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy? Hims & Hers Health grew its revenue by 49% last quarter. The company incurred a loss, however, as its gross margins deteriorated.
View source ↗ - 4chan /biz/biz·6d ago·Positive
is HIMS a good buy at $14 (where it's headed)? everyones on peptides nowadays
View source ↗ - Newsfool.com·8d ago·Negative
Why Is Hims Stock Crashing, and is it a Buying Opportunity? Revenue is increasing, but so are its operating expenses.
View source ↗ - Newsfool.com·9d ago·Negative
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push? Hims & Hers stock is facing margin pressure as it increases sales of branded weight-loss drugs and expands internationally. The company has a big opportunity in the peptide market.
View source ↗ - Newszacks.com·9d ago·Negative
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.
View source ↗ - Newszacks.com·9d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsmarketbeat.com·10d ago·Negative
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off Even a nearly 9% rebound on Wednesday, Nov. 11, couldn't undo a punishing start to the week for Hims & Hers Health NYSE: HIMS. Shares had already plunged nearly 12% ahead of Monday evening's Q3 earnings report, and disappointing results—a double miss—sent the stock tumbling another 16.6% on Tuesday.
View source ↗ - 4chan /biz/biz·11d ago·Neutral
>HIMS Maybe I *am* going to make it after all (I will if it goes to 100)
View source ↗ - 4chan /biz/biz·11d ago·Neutral
>HIMS
View source ↗ - Newsbenzinga.com·11d ago·Negative
Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.
View source ↗ - News (RSS)investing·12d ago·Neutral
Five US states join FTC suit over alleged Hims & Hers unlawful practices
View source ↗ - Newszacks.com·12d ago·Negative
HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure Hims & Hers shifts focus on weight-loss expansion and international growth as Q3 margin pressure, subscriber losses and reduced profit guidance cloud its near-term outlook.
View source ↗ - News (RSS)investing·12d ago·Neutral
Hims & Hers to offer unapproved peptides after US eases curbs
View source ↗ - News247wallst.com·12d ago·Negative
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%.
View source ↗ - News247wallst.com·12d ago·Neutral
Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week.
View source ↗ - News (RSS)fool·12d ago·Neutral
Hims & Hers: 3 Key Takeaways for Long-Term Investors Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.
View source ↗ - Newsyoutube.com·12d ago·Negative
HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth company's guidance.
View source ↗ - News (RSS)investing·12d ago·Neutral
Why is Hims & Hers Health stock sliding today?
View source ↗ - News (RSS)investing·12d ago·Neutral
Why is Hims & Hers Health stock sliding today?
View source ↗ - Newsseekingalpha.com·12d ago·Negative
Hims & Hers: Why I'm Not Buying Back Yet (Rating Downgrade) Hims & Hers grew Q3 revenue 49% to $890.4 million, but adjusted EBITDA increased just $4 million to $82.4 million. Gross margin contracted from 73.8% to 57.2%, while subscribers declined 100,000 sequentially despite rising revenue per subscriber. International revenue surged 321% to $233.3 million, although acquired Eucalyptus contributed approximately $135 million of quarterly sales.
View source ↗ - News247wallst.com·12d ago·Negative
Hims & Hers Just Warned Investors for the Third Time This Year. CEO Andrew Dudum Calls the Subscriber Losses a Trade He'll Make ‘Every Time' Hims & Hers cut its 2026 adjusted EBITDA outlook for the third time this year, to $257 million to $277 million from February's $300 million to $375 million, posted a surprise $33 million loss, and CEO Andrew Dudum called the subscriber losses a trade he will make "every time." Here is what the cut does to the valuation, how the stock has traded after past r
View source ↗ - Newsfool.com·12d ago·Positive
Hims & Hers: 3 Key Takeaways for Long-Term Investors Revenue grew 49% year-over-year to $890 million in the third quarter. Subscribers reached 2.8 million despite a 100,000 net subscriber decline.
View source ↗ - Newsmarketbeat.com·12d ago·Negative
What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call Hims & Hers Health NYSE: HIMS reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and consolidated brands in international markets.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Hims & Hers Health, Inc. (HIMS) Q3 2026 Earnings Call Transcript Hims & Hers Health, Inc. ( HIMS ) Q3 2026 Earnings Call November 9, 2026 5:00 PM EST Company Participants William Newby - Senior Director of Investor Relations Andrew Dudum - Co-Founder, Chairman & CEO Mohamed ElShenawy - Chief Technology Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Maria Ripps - Canaccord Genuity Corp., Research Division Ryan MacDonald - Needham & Company, LLC, Research Division Craig …
View source ↗ - 4chan /biz/biz·13d ago·Neutral
Anyone looking at HIMS before earnings, down 10% today and 20 for the month
View source ↗ - Newszacks.com·13d ago·Neutral
Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·13d ago·Negative
Hims & Hers Health, Inc. (HIMS) Q3 Earnings and Revenues Miss Estimates Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.06 per share a year ago.
View source ↗ - Newswsj.com·13d ago·Neutral
Hims & Hers Narrows Sales Outlook The digital healthcare company narrowed its full-year revenue outlook after third-quarter sales came in lower than expected.
View source ↗ - 4chan /biz/biz·13d ago·Neutral
>>62879608 RKLB, ASTS, TTWO, HIMS interesting day, I remember some anons talking about hims months ago, assume it's not going great as it gets no mentions anymore
View source ↗ - Newsbenzinga.com·13d ago·Negative
Hims & Hers Stock Slips Further as Q3 Print Disappoints Hims & Hers Health Inc. (NYSE:HIMS) posted its third-quarter fiscal 2026 results after Monday's closing bell, missing the Street's expectations on the top and bottom lines.
View source ↗ - Newsreuters.com·13d ago·Neutral
Hims & Hers narrows 2026 revenue forecast as margins contract Hims & Hers narrows 2026 revenue forecast as margins contract
View source ↗ - Newsbenzinga.com·13d ago·Negative
Hims & Hers Stock Plunges Before Earnings: What to Watch Hims & Hers Health Inc. (NYSE:HIMS) shares are plummeting Monday ahead of its third-quarter earnings report, which is scheduled for release after the market close.
View source ↗ - News (RSS)fool·15d ago·Positive
Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027? Both are disruptors, but one of these growth stocks stands out over the other.
View source ↗ - Newszacks.com·16d ago·Negative
HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance? Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.
View source ↗ - Newsbarrons.com·16d ago·Neutral
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
View source ↗ - Newszacks.com·17d ago·Neutral
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $24.06, indicating a -9.75% shift from the previous trading day.
View source ↗ - Newszacks.com·24d ago·Positive
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.69, marking a +1.24% move from the previous day.
View source ↗ - News (RSS)seekingalpha·25d ago·Neutral
Hims & Hers rises as U.S. to allow compounding of six peptides
View source ↗ - Newszacks.com·26d ago·Neutral
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·30d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.71, marking a -4.87% move from the previous day.
View source ↗ - Newsbenzinga.com·30d ago·Positive
Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit Hims & Hers Health Inc. (NYSE:HIMS) urged a court to throw out a consumer deception lawsuit, asserting that plaintiffs ignored clear, upfront disclosures regarding data privacy, subscription charges, and cancellation policies.
View source ↗ - Newsinvezz.com·33d ago·Positive
Hims & Hers stock rises 5% as company launches men's weight care in Germany Shares of Hims & Hers Health (HIMS) rose 5% on Tuesday after the telehealth company launched an online weight-management service for men in Germany, expanding its presence in Europe. The new offering allows patients to complete private online consultations and, if eligible, receive prescriptions from clinicians licensed in the European Union, along with ongoing support.
View source ↗ - News (RSS)fool·33d ago·Neutral
Hims Is Reaching the Three Million Member Milestone Several catalysts could sustain robust growth for Hims.
View source ↗ - Newsfool.com·34d ago·Positive
Hims Is Reaching the Three Million Member Milestone The healthcare industry is ripe for disruption.
View source ↗ - Newszacks.com·37d ago·Neutral
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newszacks.com·39d ago·Negative
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.72, denoting a -6.7% move from the preceding trading day.
View source ↗ - Newszacks.com·39d ago·Neutral
Hims & Hers Expands Australian Women's Health Platform With Hers HIMS expands into Australia's women's healthcare market with the Hers launch, offering personalized treatments for weight, hormonal health and hair regrowth.
View source ↗ - News (RSS)seekingalpha·40d ago·Positive
Hims & Hers Health: The Bullish Case Is Hard To Forecast, But It Is Asymmetrical
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Hims & Hers Health: The Bullish Case Is Hard To Forecast, But It Is Asymmetrical Hims & Hers Health is rated a buy, with a fair value estimate of $41 per share versus the current $29.81. I see the market overly discounting HIMS due to regulatory uncertainty, while the Novo partnership could drive over 50% new subscribers annually. Core business assumptions are conservative: 17% revenue CAGR, 18% EBITDA margin by 2030, and peptides modeled as an upside option worth $3 per share in the base case.
View source ↗ - Newsbusinesswire.com·41d ago·Neutral
Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026 SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, today announced that it will report third quarter 2026 financial results after the market closes on Monday, November 9, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (833) 461-578…
View source ↗ - News (RSS)investing·44d ago·Neutral
HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
View source ↗ - Newszacks.com·45d ago·Neutral
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $28.06, moving 5.01% from the previous trading session.
View source ↗ - Newszacks.com·45d ago·Negative
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now HIMS' top line is driven by demand for weight loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
View source ↗ - Newsbusinesswire.com·46d ago·Neutral
Hims & Hers Names Jon Franklin as Chief Accounting Officer SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced Jon Franklin has joined the company as Chief Accounting Officer. Franklin, a CPA with two decades of technical accounting experience across public accounting and corporate controllership, will oversee the company's accounting organization, reporting to Chief Financial Officer Yemi Okupe. "We're funding t…
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Tax Gain Harvesting: Tax Alpha With Raul Shah Raul Shah emphasizes ultra-selective value investing, focusing on high-conviction positions like HIMS, NOW, UNH, and MSFT, prioritizing long-term cash flows over daily price moves. Tax gain harvesting is the 2nd most powerful tax strategy after Roth conversions, enabling investors to realize long-term capital gains at a 0% tax rate within specific income thresholds.
View source ↗ - Newszacks.com·48d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - News (Marketaux)economictimes.indiatimes.com·50d ago·Positive
Robinhood stock tokens turbocharge a new era of meme trading He bought a memecoin paired with Him[+326 characters]
View source ↗ - Newszacks.com·52d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.3, marking a -1.64% move from the previous day.
View source ↗ - News (RSS)seekingalpha·52d ago·Neutral
Hims & Hers Goes Global - Renewed Growth Prospects With Margin Risks
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Hims & Hers: U.S. Revenue Reacceleration Is Reassuring, And Valuation Compression Is Compelling (Upgrade) Hims & Hers is upgraded to a buy as revenue growth reaccelerates and valuation compresses, offering a compelling entry point. HIMS targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, implying a >20% revenue and ~44% EBITDA CAGR from 2026-2030. Recent Q2 results showed 38% y/y revenue growth (31% organic), a strong U.S. rebound, and nearly 3M subscribers, despite margin pressure.
View source ↗ - Newszacks.com·60d ago·Neutral
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $28.39, moving 6.7% from the previous trading session.
View source ↗ - 4chan /biz/biz·61d ago·Positive
Oh and if anyone is wondering why HIMS dropped 5% in 5 minutes, thats because i fullported into calls.
View source ↗ - Newsprnewswire.com·62d ago·Negative
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Sept. 21, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newszacks.com·62d ago·Neutral
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - News (RSS)fool·64d ago·Negative
Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 Shares The insider still retains significant holdings, valued at $8.5 million, despite the sale.
View source ↗ - Newsfool.com·64d ago·Negative
Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 Shares The transaction involved shares equal to 2% of the stake held before the filing. The executive retains direct ownership of approximately 304,000 shares following the completion of the sale.
View source ↗ - Newsprnewswire.com·65d ago·Negative
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Sept. 18, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsfool.com·67d ago·Positive
Is Hims & Hers Stock a Buy Right Now in September? The healthcare industry is ripe for disruptions.
View source ↗ - Newszacks.com·68d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Falls More Steeply Than Broader Market: What Investors Need to Know In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.93, indicating a -3.07% shift from the previous trading day.
View source ↗ - News (RSS)seekingalpha·69d ago·Neutral
Hims & Hers: Pivot To Branded Distribution Is Eating The Margins Alive
View source ↗ - Newsschaeffersresearch.com·69d ago·Negative
HIMS Bulls Should Heed This Historic Chart Signal Drugmaker Hims & Hers Health Inc (NYSE:HIMS) stock is moving 6.6% higher to trade at $29.34 this afternoon.
View source ↗ - Newsfool.com·70d ago·Neutral
I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026 Hims & Hers Health is expected to grow revenue sharply in 2027. Subscriber growth and rising revenue per subscriber continue to strengthen the company's operational momentum.
View source ↗ - News (Marketaux)gurufocus.com·72d ago·Positive
HIMS Assumes Neutral Rating by JP Morgan -- Price Target Announced at $32 Hims & Hers Health[+211 characters]
View source ↗ - News (RSS)investing·72d ago·Neutral
JPMorgan cautious on Hims & Hers on GLP-1 transition risk
View source ↗ - Newszacks.com·74d ago·Neutral
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report? Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·75d ago·Positive
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.
View source ↗ - Newszacks.com·75d ago·Neutral
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsfeeds.newsfilecorp.com·76d ago·Neutral
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - September 7, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
View source ↗ - News (RSS)decrypt·79d ago·Negative
Crypto Traders Are Pairing Meme Coins With Stocks on Robinhood—And It's Working (Sort Of) A meme coin called BONER cornered half of Hims & Hers Health's tokenized shares on Robinhood's new blockchain. It started a new trend that's spreading fast.
View source ↗ - Newsbusinesswire.com·81d ago·Negative
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newszacks.com·81d ago·Negative
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
View source ↗ - Newszacks.com·81d ago·Negative
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
View source ↗ - Newsbusinesswire.com·82d ago·Negative
Stockholder Alert: Robbins LLP Informs Investors of the Hims & Hers Health, Inc. Class Action SAN DIEGO--(BUSINESS WIRE)---- $HIMS #HIMS--The complaint alleges that Hims shared customers' protected health information with advertisers and engaged in other deceptive advertising practices.
View source ↗ - Newsproactiveinvestors.com·82d ago·Negative
Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in compounding and that it has already warned companies marketing unapproved retatrutide directly to consumers.
View source ↗ - News (RSS)yahoo·82d ago·Neutral
Hims & Hers’ Australia Expansion Adds Growth, But Execution Will Be Key
View source ↗ - Newsbusinesswire.com·83d ago·Neutral
Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus…
View source ↗ - Newsbusinesswire.com·83d ago·Neutral
Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becomes Hims. Patients will maintai
View source ↗ - Newsglobenewswire.com·83d ago·Neutral
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) PHILADELPHIA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers” or the “Company”) for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared…
View source ↗ - Newsseekingalpha.com·83d ago·Positive
…ms & Hers Health is building a vertically integrated consumer-health distribution platform, with value driven by its scalable engine rather than individual products. HIMS demonstrates accelerating growth, with multiple product lines surpassing $100M ARR and rapid vertical launches, supporting a strong buy rating and a $111 price target for 2026. Q2 results showed robust revenue growth (38%) and strong Q3 guidance (47-50%), despite margin compression from branded weight-loss and international exp…
View source ↗ - 4chan /biz/biz·83d ago·Positive
…o a new meta of memecoins with taxes that accumulate the tokenized stock they're paired with to try to gain a seat on the board of the company itself. AI/NVDA, BONER/HIMS, and CINEMA/AMC are the most interesting pairs I've seen so far, though there are a lot of promising ones out there.
View source ↗ - News (RSS)yahoo·86d ago·Neutral
Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company
View source ↗ - Newsfool.com·86d ago·Positive
After Doubling in Six Months, Is it Too Late to Buy Hims & Hers Stock? The share price is up over 100% in the previous six months.
View source ↗ - Newsnewsfilecorp.com·86d ago·Negative
Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) for Potential Violations of the Federal Securities Laws New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist i…
View source ↗ - News (RSS)seekingalpha·87d ago·Neutral
Hims & Hers Is Growing Into Something Much Bigger
View source ↗ - Newsseekingalpha.com·87d ago·Neutral
Hims & Hers Is Growing Into Something Much Bigger Hims & Hers approaches 3 million subscribers as U.S. growth reaccelerates and international markets emerge as a meaningful second growth engine. International revenue reached $131 million, while testosterone is approaching Hims' sixth U.S. specialty above a $100 million annual run rate. Gross margin fell to 64%, while Q2 free cash flow reached negative $68 million, making operating leverage the critical next test.
View source ↗ - Newsnewsfilecorp.com·88d ago·Negative
Kaplan Fox & Kilsheimer LLP is Investigating Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist i…
View source ↗ - Newsnewsfilecorp.com·88d ago·Neutral
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS) Philadelphia, Pennsylvania--(Newsfile Corp. - August 26, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improp…
View source ↗ - Newsglobenewswire.com·89d ago·Negative
Hims & Hers Health, Inc. Investigated by the Portnoy Law Firm LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc., (“Hims" or the "Company") (NYSE: HIMS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $-0.03 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.14 vs $0.06miss
- Mon, Aug 10$-0.37 vs $-0.05miss
- Mon, May 11$-0.40 vs $0.03miss
- Mon, Feb 23$0.07 vs $0.02beat
- Mon, Nov 3$0.06 vs $0.09miss
- Mon, Aug 4$0.17 vs $0.18miss
Estimates and results for HIMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HIMS officers and directors.
- Bought
- —
- Sold
- $4.4m
0 trades
16 trades
- Okupe Oluyemisold
- Autor Deborah M.sold
- Boughton Soleilsold
- Boughton Soleilsold
- Boughton Soleilsold
- Okupe Oluyemisold
- Boughton Soleilsold
- Okupe Oluyemisold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
